Markets:

Overview

News

Currencies

International

Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

370.48 -15.52 (-4.02%)

Official Closing Price Updated: 7:00 PM EST, Nov 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 Next >

Bio-Rad (BIO) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Digital PCR demand and cost cuts shaped a quarter despite academic softness.

Via The Motley Fool

Topics Earnings

What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call ↗

November 05, 2026

Bio-Rad Laboratories (NYSE:BIO) reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset...

Via MarketBeat

Topics Earnings

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth ↗

September 25, 2026

Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a...

Via MarketBeat

Bio-Rad (NYSE:BIO) Falls After Q2 Beat as Life Science Sales Weigh ↗

August 04, 2026

Via Chartmill

Bio-Rad Q1 2026 Revenue Misses Estimates, Outlook Cut as NYSE:BIO Faces Cautious Trading ↗

April 30, 2026

Via Chartmill

Bio-Rad Laboratories (NYSE:BIO) Stock Plummets 12% After Q4 Earnings Miss and Weak 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Digital PCR revenue surged over 20% as clinical diagnostics grew.

Via The Motley Fool

Topics Earnings

Bio-Rad Laboratories Q2 Earnings Call Highlights ↗

August 05, 2026

Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral...

Via MarketBeat

Topics Earnings

Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? ↗

June 22, 2026

Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.

Via The Motley Fool

A Preview Of Bio-Rad Laboratories's Earnings ↗

April 30, 2025

Via Benzinga

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories ↗

May 18, 2026

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.

Via Benzinga

Bio-Rad (BIO) Q2 2025 Earnings Call Transcript ↗

May 04, 2026

Bio-Rad (BIO) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Bio-Rad (BIO) Q1 2026 Earnings Transcript ↗

May 01, 2026

Bio-Rad (BIO) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics World Trade

Bio-Rad (BIO) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Bio-Rad (BIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why a Fund Trimmed a $41 Million CompoSecure Stake Amid a 47% Stock Run ↗

December 23, 2025

Amid a monster year and, more recently, a transformative deal announcement, this move raises a sharper question about how much upside is really left at today’s valuation.

Via The Motley Fool

Topics Regulatory Compliance

Why a Fund Cut $4 Million of Payoneer Stock Despite Record Revenues ↗

December 23, 2025

Payoneer just posted record revenue and raised guidance, yet one fund trimmed its stake. The disconnect is where the real story is.

Via The Motley Fool

Topics Regulatory Compliance

Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday ↗

October 30, 2025

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Via The Motley Fool

Topics Supply Chain

Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism

October 01, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Bio-Rad (BIO) Q2 EPS Jumps 51% ↗

August 01, 2025

Via The Motley Fool

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings ↗

August 01, 2025

Via Benzinga

Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday ↗

August 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 31, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

July 31, 2025

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

5 Analysts Have This To Say About Bio-Rad Laboratories ↗

June 09, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 10, 2025

Via Benzinga

Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday? ↗

February 14, 2025

Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.